**CLAIMS**

1. A multispecific antibody or fragment thereof that specifically binds:
   a. a first target epitope, wherein the first target epitope is an epitope of the variable delta 1 (Vδ1) chain of a γδ T cell receptor (TCR); and
   b. a second target epitope, wherein the second epitope is selected from the group consisting of an epitope of CD19, Her2 (CD340), EGFR, FAPα, mesothelin, PD-1, 4-1BB, OX40 and TIGIT.

2. The multispecific antibody or fragment thereof of ~~any preceding~~ claim 1, wherein the second~~first~~ target epitope is an epitope of CD19~~within amino acid residues 1-90 of SEQ ID NO: 1 and/or SEQ ID NO: 128~~.

3. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of Her2 (CD340).

4. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of EGFR.

5. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of FAPα.

6. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of mesothelin.

7. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of PD-1.

8. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of 4-1BB.

9. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of OX40.

10. The multispecific antibody or fragment thereof of claim 1, wherein the second epitope is an epitope of TIGIT.

11~~3~~. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the first target epitope is an epitope comprising one or more amino acid residues within amino acid regions:

(i) 3-20 of SEQ ID NO: 1; and/or

(ii) 37-77 of SEQ ID NO: 1.

124. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the first target epitope is an activating epitope of a γδ T cell.

135. The multispecific antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein binding of the activating epitope: (i) downregulates the γδ TCR; (ii) activates degranulation of the γδ T cell; and/or (iii) promotes γδ T cell mediated killing.

146. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the first target epitope is an epitope that upregulates expression of CD107a, CD25, CD69 and/or Ki67.

157. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody or fragment thereof binds the first epitope with a binding affinity (KD) as measured by surface plasmon resonance of less than 1.5 x $10^{-7}$ M, less than 1.3 x $10^{-7}$ M, less than 1.0 x $10^{-7}$ M, or less than 5.0 x $10^{-8}$ M.

168. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the antibody is a bispecific antibody~~second epitope is on a Vδ1+ T cell~~.

~~9. The multispecific antibody or fragment thereof of any preceding claim, wherein the second epitope is an epitope of a cancer antigen or a cancer-associated antigen.~~

~~10. The multispecific antibody or fragment thereof of claim 9, wherein the cancer antigen or cancer- associated antigen is selected from the group consisting of AFP, AKAP-4, ALK, alpha- fetoprotein, Androgen receptor, B7H3, BAGE, BCA225, BCAA, Bcr-abl, beta-Catenin, beta-HCG, beta-human chorionic gonadotropin, BORIS, BTAA, CA 125, CA 15-3, CA 195, CA 19-9, CA 242, CA 27.29, CA 72-4, CA-50, CAM 17.1, CAM43, Carbonic anhydrase IX, carcinoembryonic antigen, CD22, CD33/IL3Ra, CD68\P1, CDK4, CEA, chondroitin sulfate proteoglycan 4 (CSPG4) , c-Met, CO-029, CSPG4, Cyclin B1, cyclophilin C-associated protein, CYP1B1, E2A-PRL, EGFR, EGFRvIII, ELF2M, EpCAM, EphA2, EphrinB2, Epstein Barr virus antigens EBVA , ERG (TMPRSS2ETS fusion gene), ETV6-AML, FAP, FGF-5, Fos-related antigen 1, Fucosyl GM1, G250, Ga733\EpCAM, GAGE-1, GAGE-2, GD2, GD3, glioma associated antigen, GloboH, Glycolipid F77, GM3, GP 100, GP 100 (Pmel 17), H4-RET, HER-2/neu, HER-2/Neu/ErbB-2, high-molecular-weight melanoma-associated antigen (HMW-MAA), HPV E6, HPV E7, hTERT, HTgp-175, human telomerase reverse transcriptase, Idiotype, IGF-I receptor , IGF-II, IGH-IGK, insulin growth factor (IGF)-I, intestinal carboxyl esterase, K-ras, LAGE-1a, LCK, lectin-reactive AFP, Legumain, LMP2, M344, MA-50, Mac-2~~

binding protein, MAD-CT-1, MAD-CT-2, MAGE, MAGE-A1, MAGE-A3, MAGE-1, MAGE-3, MAGE-4, MAGE-5, MAGE-6, MART-1, MART-1/MelanA, M-CSF, melanoma-associated chondroitin sulfate proteoglycan (MCSP), Mesothelin, MG7-Ag, ML-IAP, MN-CA IX, MOV18, MUC1, Mum-1, hsp70-2, MYCN, MYL-RAR, NA17, NB/70K, neuron-glial antigen 2 (NG2), neutrophil elastase, nm-23H1, NuMa, NY-BR-1, NY-CO-1, NY-ESO, NY-ESO-1, NY-ESO-1, OY-TES1, p15, p16, p180erbB3, p185erbB2, p53, p53 mutant, Page4, PAX3, PAX5, PDGFR-beta, PLAC1, Polysialic Acid, prostate-carcinoma tumor antigen-1 (PCTA-1), prostate-specific antigen, prostatic acid phosphatase (PAP), Proteinase3 (PR1), PSA, PSCA, PSMA, RAGE-1, Ras, Ras-mutant, RCAS1, RGS5, RhoC, ROR1, RU1, RU2 (AS), SART3, SDCCAG16, sLe(a), Sperm protein 17, SSX2, STn, Survivin, TA-90, TAAL6, a TAG-72, telomerase, thyroglobulin, Tie-2, TLP, Tn, TPS, TRP-1, TRP-2, TRP-2, TSP-180, Tyrosinase, VEGF, VEGFR2, VISTA, WT1, XAGE 1, 43-9F, 5T4, and 791Tgp72.

11. The multispecific antibody or fragment thereof of any preceding claim, wherein the multispecific antibody is a T-cell engager bispecific antibody.

12. The multispecific antibody or fragment thereof of any preceding claim, wherein the antibody is a bispecific antibody, and the second epitope is an epitope of CD19, Her2 (CD340),EGFR, FAPα or mesothelin.

13. The multispecific antibody or fragment thereof of any preceding claim, wherein the second epitope is on an immune cell.

14. The multispecific antibody or fragment thereof of any one of claims 1 to 8 or claim 13, wherein the second epitope is an epitope of an immunomodulatory antigen.

15. The multispecific antibody or fragment thereof of claim 14, wherein the immunomodulatory antigen may be selected from the group consisting of B7-1 (CD80), B7-2 (CD86), B7-DC (CD273), B7-H1 (CD274), B7-H2 (CD275), B7-H3 (CD276), B7-H4 (VTCN1), B7-H5 (VISTA), BTLA (CD272), 4-1BB (CD137), CD137L, CD24, CD27, CD28, CD38, CD40, CD40L (CD154), CD54, CD59, CD70, CTLA4 (CD152), CXCL9, GITR (CD357), HVEM (CD270), ICAM-1 (CD54), ICOS (CD278), LAG-3 (CD223), OX40 (CD134), OX40L (CD252), PD-1 (CD279), PD- L1 (CD274), TIGIT, CD314, CD334, CD335, CD337, and TIM-3 (CD366).

16. The multispecific antibody or fragment thereof of any of claims 1 to 8 or 13 to 15, wherein the antibody is a bispecific antibody, and the second epitope is an epitope of PD-1, 4-1BB, OX40 or TIGIT.

17. The multispecific antibody or fragment thereof of any preceding claim, wherein the second target epitope is an epitope of a cluster of differentiation CD antigen.

18. The multispecific antibody or fragment thereof of claim 17, wherein the CD antigen is selected from the group consisting of CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD11d, CD13, CD14, CD15, CD16, CD16a, CD16b, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32A, CD32B, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60a, CD60b, CD60c, CD61, CD62E, CD62L, CD62P, CD63, CD64a, CD65, CD65s, CD66a, CD66b, CD66c, CD66d, CD66e, CD66f, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD75s, CD77, CD79A, CD79B, CD80, CD81, CD82, CD83, CD84, CD85A, CD85B, CD85C, CD85D, CD85F, CD85G, CD85H, CD85I, CD85J, CD85K, CD85M, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107, CD107a, CD107b, CD108, CD109, CD110, CD111, CD112, CD113, CD114, CD115, CD116, CD117, CD118, CD119, CD120, CD120a, CD120b, CD121a, CD121b, CD122, CD123, CD124, CD125, CD126, CD127, CD129, CD130, CD131, CD132, CD133, CD134, CD135, CD136, CD137, CD138, CD139, CD140A, CD140B, CD141, CD142, CD143, CD144, CDw145, CD146, CD147, CD148, CD150, CD151, CD152, CD153, CD154, CD155, CD156, CD156a, CD156b, CD156c, CD157, CD158, CD158A, CD158B1, CD158B2, CD158C, CD158D, CD158E1, CD158E2, CD158F1, CD158F2, CD158G, CD158H, CD158I, CD158J, CD158K, CD159a, CD159c, CD160, CD161, CD162, CD163, CD164, CD165, CD166, CD167a, CD167b, CD168, CD169, CD170, CD171, CD172a, CD172b, CD172g, CD173, CD174, CD175, CD175s, CD176, CD177, CD178, CD179a, CD179b, CD180, CD181, CD182, CD183, CD184, CD185, CD186, CD187, CD188, CD189, CD190, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CDw198, CDw199, CD200, CD201, CD202b, CD203c, CD204, CD205, CD206, CD207, CD208, CD209, CD210, CDw210a, CDw210b, CD211, CD212, CD213a1, CD213a2, CD214, CD215, CD216, CD217, CD218a, CD218b, CD219, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD231, CD232, CD233, CD234, CD235a, CD235b, CD236, CD237, CD238, CD239, CD240CE, CD240D, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD250, CD251, CD252, CD253, CD254, CD255, CD256, CD257, CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD265, CD266, CD267, CD268, CD269, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD285, CD286, CD287, CD288, CD289, CD290, CD291, CD292, CDw293, CD294, CD295, CD296, CD297, CD298, CD299, CD300A, CD300C, CD301, CD302, CD303, CD304, CD305, CD306, CD307, CD307a, CD307b, CD307c, CD307d, CD307e, CD308, CD309, CD310, CD311, CD312, CD313, CD314, CD315, CD316, CD317, CD318, CD319, CD320, CD321, CD322, CD323, CD324, CD325, CD326, CD327, CD328, CD329, CD330, CD331, CD332, CD333, CD334, CD335, CD336,

~~CD337, CD338, CD339, CD340, CD344, CD349, CD351, CD352, CD353, CD354, CD355, CD357, CD358, CD360, CD361, CD362, CD363, CD364, CD365, CD366, CD367, CD368, CD369, CD370, and CD371.~~

~~19. The multispecific antibody or fragment thereof of any preceding claim, wherein the multispecific antibody or fragment thereof is a multispecific antibody selected from the group consisting of CrossMab, DAF (two-in-one), DAF (four-in-one), DutaMab, DT-IgG, Knobs-in-holes (KIH), Knobs-in-holes (common light chain), Charge pair, Fab-arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, κλ-body, orthogonal Fab, DVD-IgG, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zybody, DVI-IgG(four-in-one), Nanobody, Nanoby-HAS, BiTE, Diabody, DART, TandAb, scDiabody, scDiabody-CH3, Diabody-CH3, Triple Body, Morrison formats, Miniantibody, Minibody, TriBi minibody, scFv-CH3 KIH, Fab-scFv, scFv-CH-CL-scFv, F(ab')2, F(ab)2-scFv2, scFv-KIH, Fab-scFv-Fc, Tetravalent HCAb, scDiabody-Fc, Diabody-Fc, Tandem scFv-Fc, Intrabody, Dock and Lock, ImmTAC, HSAbody, scDiabody-HAS, Tandem scFv-Toxin, IgG-IgG, ov-X-Body, duobody, mab$^2$ and scFv1-PEG-scFv2.~~

17~~20~~. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody or fragment thereof is a human antibody or antigen-binding fragment thereof.

18~~21~~. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody or antigen-binding fragment thereof is an IgG multispecific antibody, optionally wherein the multispecific antibody or antigen-binding fragment thereof is an IgG1 multispecific antibody.

19~~22~~. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody is Fc-enabled.

20~~23~~. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody is characterised in that it:

a. causes downregulation of TCRs on Vδ1 T-cells;
b. does not exhibit CDC or ADCC; and
c. does not deplete Vδ1 T-cells.

21~~24~~. The multispecific antibody or fragment thereof of any one of the preceding claims, wherein the multispecific antibody causes a depletion of less than about 30%, or less than about 20%, or less than about 10% of the viable Vδ1 T+ cell population via ADCC and/or CDC.

~~25. A method of generating a recombinant multispecific antibody of any preceding claim, comprising the steps of~~

~~a. selecting a first monospecific antibody which specifically binds a first target epitope, wherein the first target epitope is an epitope of the variable delta 1 (Vδ1) chain of a γδ T cell receptor (TCR);~~

~~b. combining the antibody or antigen-binding fragment thereof of said first antibody with an antibody or fragment thereof comprising a binding domain targeting a second epitope to generate the recombinant multispecific antibody, optionally wherein the recombinant multispecific antibody is a multispecific antibody as defined in any one of claims 1 to 24.~~

2226. A pharmaceutical composition comprising the multispecific antibody or fragment thereof as defined in any one of claims 1 to 214 and a pharmaceutically acceptable diluent or carrier.

~~27. A method of treating a disease or disorder in a subject or a method of modulating an immune response in a subject, comprising administering to the subject a multispecific antibody or fragment thereof of any one of claims 1 to 24, or the pharmaceutical composition of claim 26.~~

~~28. The method of claim 27, wherein the disease or disorder is cancer, an infectious disease or an inflammatory disease, or wherein the subject in which an immune response is modulated has cancer, an infectious disease or an inflammatory disease.~~

~~29. The method of claim 27 or claim 28, wherein modulating an immune response in a subject comprises at least one selected from the group consisting of activating γδ T cells, causing or increasing proliferation γδ T cells, causing or increasing expansion of γδ T cells, causing or increasing γδ T cell degranulation, causing or increasing γδ T cell killing activity, causing or increasing γδ T cytotoxicity, causing or increasing γδ T cell mobilization, increasing survival of γδ T cells, and increasing resistance to exhaustion of γδ T cells.~~

~~30. The method of any one of claims 27 to 29, wherein diseased cells are killed while healthy cells are spared.~~

2331. A~~The~~ multispecific antibody or fragment thereof of any one of claims 1 to 2124, or the pharmaceutical composition of claim 2226, for use in ~~the~~ treating a~~ment of cancer, an infectious~~ disease or disorder in a subject~~an inflammatory disease~~.

24. The multispecific antibody or fragment thereof for use according to claim 23, wherein the disease or disorder is cancer, an infectious disease or an inflammatory disease.